Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30871266 | 0.89 | PLK1 (0.45) | PLK1ALDH1A1HPGDHTTLMNA | |
| SCHEMBL5678411 | 0.86 | CA1 (0.56) | ALDH1A1HTTLMNAL3MBTL1CYP3A4 | |
| SCHEMBL9473662 | 0.86 | ALDH1A1 (0.50) | ALDH1A1HPGDHTTLMNAL3MBTL1 | |
| SCHEMBL2303854 | 0.86 | ALDH1A1 (0.69) | PLK1ALDH1A1HPGDHTTLMNA | |
| SCHEMBL30871085 | 0.86 | ALDH1A1 (0.69) | PLK1ALDH1A1HPGDHTTLMNA | |
| SCHEMBL4151619 | 0.84 | CYP1A2 (0.66) | PLK1ALDH1A1HPGDCYP3A4TSHR | |
| SCHEMBL17486760 | 0.83 | TOP1 (0.50) | PLK1ALDH1A1HPGDHTTTSHR | |
| SCHEMBL12825437 | 0.83 | ALDH1A1 (0.52) | ALDH1A1HTTLMNAL3MBTL1CYP3A4 | |
| SCHEMBL155160 | 0.82 | MAPT (0.62) | ALDH1A1HPGDHTTLMNAL3MBTL1 | |
| SCHEMBL2546019 | 0.82 | HTR4 (0.56) | ALDH1A1HTTLMNAL3MBTL1HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012007409-A1 | N-SUBSTITUTED PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | claimed |
| EP-0087951-B1 | PHENANTHROLINE DERIVATIVES | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1989-09-13 | — | — | EP | claimed |
| US-4474961-A | ANTITUMOR AGENT | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1984-10-02 | — | — | US | claimed |
| EP-0087951-A2 | Phenanthroline derivatives | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1983-09-07 | — | — | EP | claimed |
| US-12612402-B2 | Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof | NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20250304578-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF | NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250263404-A1 | AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE | UCL BUSINESS LTD (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-3965803-B1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA FARBER CANCER INST INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| CN-119350323-B | N-sulfonyl amide nitrogen-containing fused heterocycle compounds targeting p53 mutation and application thereof | 上海宇道生物技术有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119968361-A | Compounds targeting p 53Y 220 mutants | 北京加科思新药研发有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| EP-0087951-B1 | PHENANTHROLINE DERIVATIVES | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1989-09-13 | — | — | EP | disclosed |
| US-4474961-A | ANTITUMOR AGENT | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1984-10-02 | — | — | US | disclosed |
| EP-0087951-A2 | Phenanthroline derivatives | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1983-09-07 | — | — | EP | disclosed |
| US-4031073-A | Monoazo pigments containing barbituric acid or thio- or imino-derivatives thereof | CIBA-GEIGY CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | PTK2, CTTN, TNK2 | PLK1 51/4885ALDH1A1 2836/4885HPGD 2618/4885 |
| US-20250304578-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF | TP53, NPM1, TP53BP1 | PLK1 626/4885ALDH1A1 2868/4885HPGD 1429/4885 |
| US-12612402-B2 | Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NPM1 | PLK1 1013/4885ALDH1A1 3512/4885HPGD 2065/4885 |
| US-20250263404-A1 | AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE | PIK3CD, PTEN, PIK3CG | PLK1 845/4885ALDH1A1 2643/4885HPGD 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.